Levetiracetam in juvenile myoclonic epilepsy: Long-term efficacy in newly diagnosed adolescents

Developmental Medicine and Child Neurology

Volumn 50, Issue 1, 2008, Pages 29-32

  Verrotti, Alberto ^a   Cerminara, Caterina ^h   Coppola, Giangennaro ^b   Franzoni, Emilio ^c   Parisi, Pasquale ^d   Iannetti, Paola ^e   Aloisi, Paolo ^f   Tozzi, Elisabetta ^f   Cusmai, Raffaella ^f   Vigevano, Federico ^g   Chiarelli, Francesco ^a   Curatolo, Paolo ^h  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d Child Neurology and Paediatric Sleep Centre   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f UNIVERSITY OF L'AQUILA   (Italy)

^g BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^h UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ETIRACETAM;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ANTICONVULSANT THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; FEMALE; FOLLOW UP; FREQUENCY ANALYSIS; HUMAN; ITALY; LONG TERM CARE; MALE; MONOTHERAPY; MULTICENTER STUDY; MYOCLONUS EPILEPSY; ONSET AGE; PHOTOSENSITIVITY; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ANTICONVULSANTS; CHILD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MYOCLONIC EPILEPSY, JUVENILE; PIRACETAM; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 37449014099     PISSN: 00121622     EISSN: 14698749     Source Type: Journal    
DOI: 10.1111/j.1469-8749.2007.02009.x     Document Type: Article

References (27)

1. Thomas P, Genton P, Wolf P. (2005) Juvenile Myoclonic Epilepsy. In: Roger J, Dravet C, Bureau M, Genton P, Tassinari CA, Wolf P, editors. Epileptic Syndromes in Infancy, Childhood and Adolescence. London: John Libbey and Co. p 335-336.
2. Appleton R, Beirne M, Acomb B. (2000) Photosensitivity in juvenile myoclonic epilepsy. Seizure 9: 108-111.
3. Verrotti A, Manco R, Di Marco G, Chiarelli F, Franzoni E. (2006) The treatment of juvenile myoclonic epilepsy. Expert Rev Neurother 6: 847-854.
4. Erdem H, Yigit A, Culcuoglu A, Mutluer N. (2001) Effect of sodium valproate on somatosensory evoked potentials in juvenile myoclonic myoclonic epilepsy. Ups J Meds Sci 106: 197-203.
5. Isojarvi JI, Tauboll E, Tapainem JS, Pakarinen AJ, Laatikainem TJ, Knip M. (2001) On the association between valproate and polycystic ovary syndrome: A response and an alternative view. Epilepsia 42: 305-310.
6. Covanis A. (2005) Photosensitivity in idiopathic generalised epilepsies. Epilepsia 46 (Suppl. 9): 67-72.
7. Klitgaard H, Pitkanen A. (2003) Antipileptogenesis, neuroprotectian and disease modification in the treatment of epilepsy: Focus on Levetiracetam. Epileptic Disord 5 (Suppl. 1): S9-16.
8. Noyer M, Gillard M, Matagne A, Hénichart J P, Wülfert E. (1995) The noval antiepileptic drug Levetiratacetam (ucb LO59) appears to act via a specific binding site in CNS membranes. Eur J Pharmacol 286: 137-146.
9. Rigo JM, Hans G, Nguyen L, Rocher V, Belachew S, Malgrange B, Leprince P, Moonen G, Selak I, Matagne A, Klitgaard H. (2002) The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br J Pharmacol 136: 659-672.
10. Zona C, Niespodziany I, Marchetti P, Klitgaard H, Bernardi G, Margineau DG. (2001) Levetiracetam does not modulate neuronal voltage-gated Na+ and T-type Ca2+ currents. Seizure 10: 279-286.
11. Lynch BA, Lamberg N, Nocka K, Kensel-Hammes P, Bajjalich SM, Matagne A, Fuks B. (2004) The synaptic vesicle protein SV2A in the binding site for the antiepileptic drug levetiracetam. PNAS 101: 9861-9866.
12. Carunchio I, Pieri M, Ciotti MT, Albo F, Zona C. (2007) Modulation of AMPA receptors in cultured cortical neurons induced by the antiepileptic drug levetiracetam. Epilepsia 48: 654-662.
13. Di Bonaventura C, Fattouch J, Mari F, Egeo G, Vandano AE, Principe M, Manfredi M, Giallonardo AT. (2005) Clinical experience with levetiracetam in idiopathic generalized epilepsy according to different syndrome subtypes. Epileptic Disord 7: 231-235.
14. Andermann E, Andermann F, Meyvisch P, Tonner F. (2006) Efficacy and tolerability levetiracetam add-on therapy in patients with refractory idiopathic generalised epilepsy. Epilepsia 47 (Suppl. 4): 187.
15. Labate A, Colosimo E, Gambardella A, Leggio U, Ambrosio R, Quattrone A. (2006) Levetiracetam in patients with generalised epilepsy and myoclonic seizures: An open label study. Seizure 15: 214-218.
16. Brodie MJ, Perucca E, Ryvlin P, Ben-Menachem E, Meencke HJ; Levetiracetam Monotherapy Study Group. (2007) Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 68: 402-408.
17. Kasteleijn-Nolst TrenitèDGA, Marescaux C, Stodieck S, Edelbroeck PM, Oosting J. (1996) Photosensitive epilepsy: A model to study the effects of antiepileptic drugs. Evaluation of the piracetam analogue, levetiracetam. Epilepsy Res 25: 225-230.
18. Jongsma M, Jansen G, Engelsmann M, Haan D. (2002) Promising results of levetiracetam in juvenile myoclonic epilepsy. Epilepsia 43: 153.
19. Pinto A, Sander JW. (2003) Levetiracetam: A new therapeutic option for refractory epilepsy. Int J Clin Pract 57: 616-621.
20. Verdru P. (2005) Epilepsy in children: The evidence for new antiepileptic drugs. Acta Neurol Scand Suppl 181: 17-20.
21. Specchio LM, Gambardella A, Giallonardo AT, Michelacci R, Specchio N, Boero G, La Neve A. (2006) Open label, long-term, pragmatic study on levetiracetam in the treatment of juvenile myoclonic epilepsy. Epilepsy Res 71: 32-39.
22. Commission on classification and terminology of the International League Against Epilepsy. (1989) Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 30: 389-399.
23. Frucht SJ, Louis ED, Chuang C, Fahn S. (2001) A pilot tolerability and efficacy of levetiracetam in patients with chronic myoclonus. Neurology 57: 1112-1114.
24. Crest C, Dupont S, Leguern E, Adam C, Baulac M. (2004) Levetiracetam in progressive myoclonic epilepsy: An exploratory study in 9 patients. Neurology 62: 640-643.
25. Verrotti A, Greco R, Latini G, Chiarelli F. (2005) Endocrine and metabolic changes in epileptic patients receiving valproic acid. J Paediatr Endocrinol Metab 18: 423-430.
26. Greenhill L, Betts T, Yarrow H. (2002) Effect of levetiracetam on resistant juvenile myoclonic epilepsy. Seizure 11: 531.
27. Krauss GL, Betts T, Abou-Khalil B, Bergey G, Yarrow H, Miller A. (2003) Levetiracetam treatment of idiopathic generalised epilepsy. Seizure 12: 617-620.